Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 35.2 kDa. The protein migrates as 36-38 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
>90% as determined by SDS-PAGE.
This product is not suitable for cell based experiments due to cytotoxicity of DDM.
DDM and CHS are INDISPENSABLE to keep membrane protein soluble and active, under no circumastance should you remove DDM and CHS.
DDM/CHS buffer (DC-11) is sold separately and not included in protein, and please contact us if you need the buffer.
If glycerol is not compatible to your application, remove glycerol just before immediate experiment, and NEVER store glycerol-free protein solution.
Supplied as 0.2 μm filtered solution in 50 mM HEPES, 150 mM NaCl, DDM, CHS, pH7.5 with glycerol as protectant.
Contact us for customized product form or formulation.
This product is supplied and shipped with dry ice, please inquire the shipping cost.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Cynomolgus CD20 Full Length, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.
Immobilized Rituximab at 2 μg/mL (100 μL/well) can bind Cynomolgus CD20 Full Length, His Tag (Cat. No. CD0-C52H8) with a linear range of 1-31 ng/mL (QC tested).
Immobilized Ofatumumab at 2 μg/mL (100 μL/well) can bind Cynomolgus CD20 Full Length, His Tag (Cat. No. CD0-C52H8) with a linear range of 0.2-16 ng/mL (QC tested).
Immobilized Cynomolgus CD20 Full Length, His Tag (Cat. No. CD0-C52H8) at 5 μg/mL (100 μL/well) can bind Biosimilar of Obinutuzumab with a linear range of 0.3-10 ng/mL (Routinely tested).
Rituximab captured on CM5 chip via anti-human IgG Fc antibody can bind Cynomolgus CD20 Full Length, His Tag (Cat. No. CD0-C52H8) with an affinity constant of 5.48 nM as determined in a SPR assay (in presence of DDM and CHS) (Biacore T200) (Routinely tested).
Ofatumumab captured on CM5 chip via anti-human IgG Fc antibody can bind Cynomolgus CD20 Full Length, His Tag (Cat. No. CD0-C52H8) with an affinity constant of 3.51 nM as determined in a SPR assay (in presence of DDM and CHS) (Biacore T200) (Routinely tested).
Price(USD) : $805.00
Price(USD) : $2985.00
Price(USD) : $7480.00
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides comprehensive tools for neuroscience research, including neuroscience proteins, pre-formed fibrils (PFFs), neural antibodies, neural factors, and more—aiming to accelerate disease modeling, drug screening, and neural mechanism studies.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Rituximab biosimilar (Celltrion) | CT-P10 | Approved | Celltrion Inc | Truxima, Blitzima, Ritemvia, Rituzena | EU | Leukemia, Lymphocytic, Chronic, B-Cell; Granulomatosis with Polyangiitis; Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid; Microscopic Polyangiitis | Celltrion Healthcare Hungary Kft | 2017-02-17 | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Pemphigus; Leukemia, Lymphocytic, Chronic, B-Cell; Burkitt Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma; Lymphoma, T-Cell; Lymphoproliferative Disorders; Leukemia, B-Cell; Primary mediastinal B cell lymphoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, B-Cell, Marginal Zone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Arthritis, Rheumatoid; Lymphoma, Large B-Cell, Diffuse; Anemia; Microscopic Polyangiitis; Leukemia, Lymphoid; Granulomatosis with Polyangiitis; Lymphoma, B-Cell; Leukemia, Myelogenous, Chronic; Leukemia, Myeloid, Accelerated Phase | Details |
Hyaluronidase/Rituximab | Approved | Genentech Inc | Rituxan Hycela | United States | Lymphoma, Large B-Cell, Diffuse; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular | Genentech Inc | 2017-06-22 | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
Ublituximab | TG-1101; TGTX-1101; LFB-R603; TG-1303; EMAB-6; R-603 | Approved | Tg Therapeutics Inc | Utuxin, BRIUMVI | United States | Multiple Sclerosis | Tg Therapeutics Inc | 2022-12-28 | Lymphoma, B-Cell, Marginal Zone; Multiple Sclerosis, Relapsing-Remitting; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Multiple Sclerosis; Lymphoma, Follicular; Neuromyelitis Optica; Richter's Syndrome; Lymphoma, Mantle-Cell; Lymphoma; Waldenstrom Macroglobulinemia; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell; Central Nervous System Lymphoma | Details |
Rituximab Biosimilar(Shanghai Institute Of Biological Products) | SIBP-02 | Approved | Shanghai Institute Of Biological Products Co Ltd | 生利健 | Mainland China | Lymphoma, Large B-Cell, Diffuse; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular | Shanghai Institute Of Biological Products Co Ltd | 2024-03-19 | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Ibritumomab tiuxetan | IDEC-In2B8; BAY86-5128; SHL-749; IDEC-Y2B8; IDEC-129; IDEC-2B8-MX-DTPA | Approved | Biogen Inc | Zevalin, Zavalin | United States | Lymphoma, B-Cell | Spectrum Pharmaceuticals Inc | 2002-02-19 | Lymphoma, B-Cell, Marginal Zone; Lymphoma, B-Cell; Leukemia, Lymphoid; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Waldenstrom Macroglobulinemia; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Zuberitamab | HS-006 | Approved | Zhejiang Hisun Pharmaceutical Co Ltd | 安瑞昔 | Mainland China | Lymphoma, Large B-Cell, Diffuse | BioRay Pharmaceutical Co Ltd | 2023-05-12 | Purpura, Thrombocytopenic, Idiopathic; Nephrosis; Lymphoma, Large B-Cell, Diffuse; Arthritis, Rheumatoid; Glomerulonephritis, Membranous; Thrombocytopenia; Lymphoma, Non-Hodgkin | Details |
Odronextamab | REGN-1979 | Approved | Regeneron Pharmaceuticals Inc | ORDSPONO | EU | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular | Regeneron Pharmaceuticals Inc | 2024-08-26 | Lymphoma, B-Cell, Marginal Zone; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Ofatumumab | GSK-1841157; 2F2; OMB-157; HuMax-CD2 | Approved | Genmab A/S | Arzerra, Kesimpta | United States | Leukemia, Lymphocytic, Chronic, B-Cell | Novartis Pharma Ag | 2009-10-26 | Leukemia; Multiple Sclerosis, Relapsing-Remitting; Arthritis, Rheumatoid; Lymphoma, Large B-Cell, Diffuse; Hodgkin Disease; Multiple Sclerosis; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Waldenstrom Macroglobulinemia; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Pemphigus | Details |
Rituximab biosimilar (Innovent Biologics) | IBI-301 | Approved | Innovent Biologics(Suzhou) Co Ltd | 达伯华, HALPRYZA | Mainland China | Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular | Innovent Biologics(Suzhou) Co Ltd | 2020-09-30 | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma; Burkitt Lymphoma; Lymphoma, T-Cell; Leukemia, B-Cell; Lymphoma, Mantle-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Lymphoma, B-Cell; Blastic Plasmacytoid Dendritic Cell Neoplasm; Neoplasms; Lymphoma, Large B-Cell, Diffuse; Anemia; Hematologic Neoplasms; Leukemia, Myelogenous, Chronic; Lymphoma, B-Cell, Marginal Zone; Leukemia, Myeloid, Accelerated Phase | Details |
Rituximab biosimilar (Sandoz) | GP-2013 | Approved | Sandoz | Riximyo, Rixathon | EU | Microscopic Polyangiitis; Pemphigus; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell; Granulomatosis with Polyangiitis; Arthritis, Rheumatoid | Sandoz Gmbh | 2017-06-15 | Lymphoma, B-Cell; Granulomatosis with Polyangiitis; Microscopic Polyangiitis; Arthritis, Rheumatoid; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Pemphigus; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Rituximab biosimilar (AryoGen Biopharma) | Approved | Aryogen Biopharma | Zytux | Iran | Leukemia, Myelogenous, Chronic; Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid; Granulomatosis with Polyangiitis; Microscopic Polyangiitis | Aryogen Biopharma | 2014-01-01 | Leukemia, Myelogenous, Chronic; Granulomatosis with Polyangiitis; Microscopic Polyangiitis; Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin | Details | |
Rituximab biosimilar (Biosidus) | Approved | Biosidus | Argentina | Hematologic Neoplasms | Biosidus | 2013-06-01 | Hematologic Neoplasms | Details | ||
Rituximab biosimilar (mAbxience) | RTXM-83; mAbx-02 | Approved | Mabxience Sa | Novex | Argentina | Lymphoma, Large B-Cell, Diffuse | Mabxience Sa | 2015-01-01 | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Burkitt Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Leukemia, B-Cell; Lymphoproliferative Disorders; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Large B-Cell, Diffuse; Anemia; Lymphoma, B-Cell; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myelogenous, Chronic | Details |
Rituximab biosimilar (Hetero Drugs) | Approved | Hetero Drugs Ltd | Maball, Mabura | India | Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular | Hetero Drugs Ltd | 2015-01-01 | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
Rituximab biosimilar (Center of Molecular Immunology) | Approved | Center Of Molecular Immunology | CIMAbior, RituxCIM | Cuba | Lymphoma, Non-Hodgkin | null | 2017-04-01 | Lymphoma, Non-Hodgkin | Details | |
Rituximab biosimilar (Biocad) | BCD-020 | Approved | BIOCAD JSC | Acellbia | Russian Federation | Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin | BIOCAD JSC | 2015-01-01 | Lymphoma, B-Cell, Marginal Zone; Arthritis, Rheumatoid; Lymphoma, Follicular; Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Rituximab biosimilar (Reliance Life Sciences) | R-TPR-017 | Approved | Reliance Life Sciences | Toritz, RituxiRel | India | Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid | null | 2016-01-01 | Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin | Details |
Rituximab biosimilar (CTTQ Pharma) | TQB-2303 | Approved | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | Mainland China | Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group | 2023-05-26 | Hematologic Neoplasms; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Blastic Plasmacytoid Dendritic Cell Neoplasm; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Burkitt Lymphoma; Lymphoma, T-Cell | Details | ||
Rituximab biosimilar (Shanghai Henlius Biotech) | HLX-01 | Approved | Shanghai Henlius Biotech Inc | 汉利康, AUDEXA | Mainland China | Lymphoma, Non-Hodgkin | Shanghai Henlius Biopharmaceuticals Co Ltd | 2019-02-22 | Lymphoma, B-Cell; Arthritis, Rheumatoid; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin | Details |
Rituximab biosimilar (Amgen) | ABP-798; APB-798 | Approved | Amgen Inc | Riabni | United States | Lymphoma, Follicular; Granulomatosis with Polyangiitis; Microscopic Polyangiitis; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma, Large B-Cell, Diffuse | Amgen Inc | 2020-12-17 | Lymphoma, Follicular; Leukemia, Lymphocytic, Chronic, B-Cell; Burkitt Lymphoma; Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Leukemia, B-Cell; Lymphoproliferative Disorders; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Plasmablastic Lymphoma; Lymphoma, Mantle-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, B-Cell, Marginal Zone; Blastic Plasmacytoid Dendritic Cell Neoplasm; Neoplasms; Lymphoma, Large B-Cell, Diffuse; Arthritis, Rheumatoid; Microscopic Polyangiitis; Anemia; Hematologic Neoplasms; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myelogenous, Chronic; Granulomatosis with Polyangiitis; Lymphoma, B-Cell | Details |
Rituximab biosimilar (Pfizer) | PF-05280586; PF-5280586 | Approved | Pfizer Inc | Ruxience | United States | Lymphoma, Non-Hodgkin; Microscopic Polyangiitis; Granulomatosis with Polyangiitis; Leukemia, Lymphocytic, Chronic, B-Cell | Pfizer Inc | 2019-07-23 | Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Pemphigus; Lymphoma; Burkitt Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Leukemia, B-Cell; Lymphoproliferative Disorders; Primary mediastinal B cell lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Plasmablastic Lymphoma; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Richter's Syndrome; Lymphoma, AIDS-Related; Lymphoma, Large B-Cell, Diffuse; Arthritis, Rheumatoid; Anemia; Leukemia, Lymphoid; Microscopic Polyangiitis; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myelogenous, Chronic; Granulomatosis with Polyangiitis; Lymphoma, B-Cell | Details |
Obinutuzumab | RG-7159; RG-7195; RO-5072759; B-HH6-B-KV1-GE; R-7159; GA-101; RG7159-7 | Approved | Genentech Inc | Gazyva, Gazyvaro, Gazyva/Gazyvaro, 佳罗华 | United States | Leukemia, Lymphocytic, Chronic, B-Cell | Genentech Inc | 2013-11-01 | Glomerulosclerosis, Focal Segmental; Central Nervous System Lymphoma; Kidney Failure, Chronic; Leukemia, Lymphocytic, Chronic, B-Cell; Nephrotic Syndrome; Lymphoma; Lymphoma, Non-Hodgkin; Waldenstrom Macroglobulinemia; Lymphoproliferative Disorders; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lupus Erythematosus, Systemic; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Lupus Nephritis; Glomerulonephritis, Membranous; Lymphoma, Large B-Cell, Diffuse; Graft vs Host Disease; Nephrosis; Leukemia, Lymphoid; Leukemia; Lymphoma, B-Cell | Details |
Rituximab biosimilar (Probiomed) | PBO-326 | Approved | Probiomed | Kikuzubam | Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin | Details | ||||
Ripertamab | SCT-400 | Approved | SinoCelltech Ltd | Mainland China | Lymphoma, Large B-Cell, Diffuse | SinoCelltech Ltd | 2022-08-23 | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Central Nervous System Lymphoma | Details | |
Rituximab | IDEC-102; IDEC-C2B8; RO-452294; R-105; RG-105 | Approved | Biogen Inc | MabThera, MabThera/Rituxan, 美罗华, Ristova, Rituxan | United States | Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid; Leukemia, Lymphocytic, Chronic, B-Cell | Genentech Inc, Idec Pharmaceuticals Corp | 1997-11-26 | Polymyositis; Granulomatosis with Polyangiitis; Purpura, Thrombocytopenic, Idiopathic; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Rejection of renal transplantation; Leukemia; Hematologic Neoplasms; Myasthenia Gravis; Ocular Motility Disorders; Lymphoma, B-Cell, Marginal Zone; Diabetes Mellitus, Type 1; Liver Cirrhosis, Biliary; Peripheral Nervous System Diseases; Opsoclonus-Myoclonus Syndrome; Multiple Sclerosis, Relapsing-Remitting; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Lymphoma, B-Cell; Keratoconjunctivitis Sicca; HIV Infections; Microscopic Polyangiitis; ST Elevation Myocardial Infarction; Rejection of liver transplantation; Scleritis; Myositis; Pulmonary Alveolar Proteinosis; Dermatomyositis; Stomach Neoplasms; Renal Insufficiency; Nephrosis; Hemophilia A; Immunoglobulin G4-Related Disease; Schizophrenia; Purpura; Arthritis, Rheumatoid; Lymphoma, Large B-Cell, Diffuse; Scleroderma, Systemic; Graft vs Host Disease; Plasmacytoma; Purpura, Thrombotic Thrombocytopenic; | Details |
Ocrelizumab | R-1594; rhuMab 2H7; RG-1594; PRO-70769; RO-4964913 | Approved | Genentech Inc | Ocrevus | United States | Multiple Sclerosis | Genentech Inc | 2017-03-28 | Multiple Sclerosis, Relapsing-Remitting; Schizophrenia; Arthritis, Rheumatoid; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis; Lupus Nephritis; Lupus Erythematosus, Systemic; Lymphoma, Non-Hodgkin; Encephalitis | Details |
rituximab biosimilar (Zenotech) | Approved | Zenotech Laboratories | India | Lymphoma, Non-Hodgkin | Zenotech Laboratories | 2013-02-01 | Lymphoma, Non-Hodgkin | Details | ||
Ocrelizumab/Hyaluronidase-ocsq | Approved | Genentech Inc | OCREVUS ZUNOVO | United States | Multiple Sclerosis | Genentech Inc | 2024-09-13 | Multiple Sclerosis | Details | |
Rituximab biosimilar (Intas Biopharmaceuticals) | Approved | Intas Biopharmaceuticals | Mabtas | India | Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin | Intas Biopharmaceuticals | 2013-01-01 | Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
Mosunetuzumab | RG-7828; BTCT-4465A; RO-7030816; CD20-TBD | Approved | Genentech Inc | Lunsumio | EU | Lymphoma, Follicular | Roche Registration Gmbh | 2022-06-03 | Lymphoma, B-Cell, Marginal Zone; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lupus Erythematosus, Systemic; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Epcoritamab | GEN-3013; ABBV-GMAB-3013 | Approved | Genmab A/S, Abbvie Inc | Tepkinly, TEPKINLY, EPKINLY | United States | Lymphoma, Large B-Cell, Diffuse | Genmab Us Inc | 2023-05-19 | Lymphoma, B-Cell, Marginal Zone; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Primary mediastinal B cell lymphoma; Richter's Syndrome; Lymphoproliferative Disorders; Lymphoma, Non-Hodgkin; Lymphoma; Waldenstrom Macroglobulinemia; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Rituximab biosimilar (Dr Reddy's Laboratories) | Approved | Dr.Reddy's Laboratories Ltd | Reditux, REDDITUX, Tidecron, Redditux | India | Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid | Dr.Reddy's Laboratories Ltd | 2007-01-01 | Arthritis, Rheumatoid; Lymphoma, Follicular; Lymphoma, Non-Hodgkin | Details | |
Glofitamab | RG-6026; RO-7082859; RG6026-2; RO6026 | Approved | F. Hoffmann-La Roche Ltd | COLUMVI, 高罗华 | Canada | Lymphoma, Large B-Cell, Diffuse | F. Hoffmann-La Roche Ltd | 2023-03-25 | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Lymphoma | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Rituximab biosimilar (Samsung) | SAIT-101 | Phase 3 Clinical | Samsung Biologics Co Ltd | Lymphoma, Follicular; Leukemia, Lymphocytic, Chronic, B-Cell; Burkitt Lymphoma; Lymphoma; Lymphoma, T-Cell; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Leukemia, B-Cell; Lymphoma, Mantle-Cell; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, B-Cell, Marginal Zone; Blastic Plasmacytoid Dendritic Cell Neoplasm; Neoplasms; Lymphoma, Large B-Cell, Diffuse; Arthritis, Rheumatoid; Anemia; Hematologic Neoplasms; Lymphoma, B-Cell; Leukemia, Myelogenous, Chronic; Leukemia, Myeloid, Accelerated Phase | Details |
Rituximab biosimilar (Boehringer Ingelheim) | BI-695500 | Phase 3 Clinical | C.H. Boehringer Sohn Ag & Co. Kg | Pancytopenia; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, T-Cell; Burkitt Lymphoma; Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, B-Cell; Lymphoproliferative Disorders; Plasmablastic Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, B-Cell, Marginal Zone; Blastic Plasmacytoid Dendritic Cell Neoplasm; Arthritis, Rheumatoid; Leukemia, Myelomonocytic, Chronic; Neoplasms; Lymphoma, Large B-Cell, Diffuse; Hodgkin Disease; Anemia; Leukemia, Myelogenous, Chronic; Leukemia, Myeloid, Accelerated Phase; Hematologic Neoplasms; Lymphoma, B-Cell | Details |
Recombinant humanized monoclonal antibody MIL62 | MIL62 | Phase 3 Clinical | Beijing Innocare Pharma Tech Co Ltd, Beijing Mabworks Biotech Co Ltd | Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Nephrosis; Lupus Nephritis; Glomerulonephritis, Membranous; Lupus Erythematosus, Systemic; Neuromyelitis Optica; Lymphoma, Follicular; Lymphoma, Non-Hodgkin | Details |
Recombinant chimeric anti-CD20 antibody (Shanghai Institute of Biological Products) | Phase 3 Clinical | Shanghai Institute Of Biological Products Co Ltd | Lymphoma, Large B-Cell, Diffuse | Details | |
Divozilimab | BCD-132 | Phase 3 Clinical | BIOCAD JSC | Scleroderma, Systemic; Multiple Sclerosis; Neuromyelitis Optica | Details |
Ocrelizumab biosimilar (CinnaGen) | Phase 3 Clinical | Cinnagen | Multiple Sclerosis | Details | |
Recombinant anti-CD20 humanized monoclonal antibody (Shanghai Pharma) | B001; B-001; B001A; B001-A; B001C; B001-C | Phase 3 Clinical | Shanghai Pharmaceuticals Holding Co Ltd | Multiple Sclerosis; Neuromyelitis Optica; Lymphoma, Non-Hodgkin; Lymphoma | Details |
BAT-4406F | BAT-4406; BAT-4406F | Phase 3 Clinical | Bio-Thera Solutions Ltd | Neuromyelitis Optica | Details |
Rituximab biosimilar (Nanjing Yoko Biomedical) | GB-241 | Phase 3 Clinical | Genor Biopharma Co Ltd, Nanjing Yoko Biomedical Co Ltd | Lymphoma, Follicular; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Burkitt Lymphoma; Lymphoma, T-Cell; Lymphoma, Non-Hodgkin; Lymphoma, Mantle-Cell; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, B-Cell, Marginal Zone; Blastic Plasmacytoid Dendritic Cell Neoplasm; Neoplasms; Lymphoma, Large B-Cell, Diffuse; Leukemia, Myelogenous, Chronic; Leukemia, Myeloid, Accelerated Phase; Hematologic Neoplasms; Lymphoma, B-Cell | Details |
Amulirafusp alfa | IMM-0306; IMC-002 | Phase 3 Clinical | ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd | Lymphoma, B-Cell; Lupus Nephritis; Neuromyelitis Optica; Lupus Erythematosus, Systemic; Lymphoma, Non-Hodgkin | Details |
Rituximab biosimilar (Hisun Pharma/Beijing Mabworks Biotech) | Phase 3 Clinical | Zhejiang Hisun Pharmaceutical Co Ltd, Beijing Mabworks Biotech Co Ltd | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin | Details | |
Ocrelizumab biosimilar(Amgen) | ABP 692 | Phase 3 Clinical | Amgen Inc | Multiple Sclerosis, Relapsing-Remitting | Details |
Ocrelizumab biosimilar (Celltrion) | CT-P53 | Phase 3 Clinical | Celltrion Inc | Multiple Sclerosis, Relapsing-Remitting | Details |
Iodine 131 tositumomab | TST/I131-TST | Phase 3 Clinical | Glaxosmithkline Plc | Lymphoma, B-Cell; Leukemia, Lymphoid; Hodgkin Disease; Multiple Myeloma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
B-007 | B-007; B007 | Phase 3 Clinical | Shanghai Pharmaceuticals Holding Co Ltd | Lymphoma, B-Cell; Myasthenia Gravis; Nephrosis; Glomerulonephritis, Membranous; Lymphoma, Non-Hodgkin; Pemphigus | Details |
Rituximab biosimilar(Shandong New Time Pharmaceutical) | H-02; F-007 | Phase 3 Clinical | Shandong New Time Pharmaceutical Co Ltd | Lymphoma, Large B-Cell, Diffuse | Details |
Anti-CD20 CART-transduced T cells (Cellular Biomedicine Group) | CART-20; CBM-C20.1; CBM-CD20 1 | Phase 2 Clinical | Pla General Hospital | Hematologic Neoplasms; Leukemia; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Lymphoma; Leukemia, Prolymphocytic; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
BVX20-CD20 antibody (Biocon/Vaccinex) | BVX-20; BVX20-MAb | Phase 2 Clinical | Biocon Ltd, Vaccinex Inc | Lymphoma, Non-Hodgkin | Details |
Anti-CD20 CAR T-cell therapy (Southwest Hospital Chongqing) | Phase 2 Clinical | The Southwest Hospital of AMU | Lymphoma, Large B-Cell, Diffuse | Details | |
Rituximab biosimilar (JHL Biotech) | JHL-1101 | Phase 2 Clinical | Eden Biologics Inc | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Arthritis, Rheumatoid; Blastic Plasmacytoid Dendritic Cell Neoplasm; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Burkitt Lymphoma | Details |
Zamtocabtagene autoleucel | MB-CART2019.1 | Phase 2 Clinical | Miltenyi Biotec | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Scleroderma, Systemic; Lupus Nephritis; Primary mediastinal B cell lymphoma; Lupus Erythematosus, Systemic; Lymphoma; Scleroderma, Diffuse; Central Nervous System Lymphoma | Details |
Allogeneic anti-CD20 CAR-T cell therapy (Precision BioSciences) | PBCAR-20A | Phase 2 Clinical | Precision Biosciences Inc | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
ELC-301 | ELC301; ELC-301 | Phase 2 Clinical | Elicera Therapeutics AB, Uppsala University | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details |
MBS-303 | MBS-303 | Phase 2 Clinical | Beijing Mabworks Biotech Co Ltd | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details |
UCART-20x22 | UCART-20x22 | Phase 2 Clinical | Cellectis Sa | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details |
bbT-369 | bbT-369 | Phase 2 Clinical | Bluebird Bio Inc | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin | Details |
GB-261 | CND261; CND-261; GB-261 | Phase 2 Clinical | Genor Biopharma Co Ltd | Lymphoma, B-Cell; Leukemia, Lymphoid; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
CHO-H01 | CHO-H01 | Phase 2 Clinical | Academia Sinica | Neoplasms; Lymphoma, Non-Hodgkin | Details |
MB-CART19.1 | Phase 2 Clinical | Miltenyi Biomedicine Gmbh | Polymyositis; Lymphoma, B-Cell; Dermatomyositis; Leukemia, Lymphoid; Scleroderma, Systemic; Lupus Erythematosus, Systemic; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
4SCAR-T cell therapy (Shenzhen Geno-Immune Medical Institute) | 4SCAR-T | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Hematologic Neoplasms; Autoimmune Diseases; Neuroblastoma | Details |
AZD-5492 | AZD5492 | Phase 2 Clinical | Astrazeneca Plc | Lymphoma, B-Cell; Neoplasms; Leukemia, B-Cell | Details |
CD19&CD20 bispecific CAR-T cells therapy(Hebei Taihe Chunyu Biotechnology) | Phase 2 Clinical | Hebei Tahoe Chunyu Biotechnology Co Ltd | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
CD3-CD20 Bisspecific Antibody Based Therapy Combined With CD19-CAR T Cells therapy(Institute Of Hematology & Blood Diseases Hospital) | Phase 2 Clinical | Institute Of Hematology & Blood Diseases Hospital | Lymphoma, B-Cell | Details | |
IPH-6501 | IPH-6501; IPH-65 | Phase 2 Clinical | Innate Pharma SA | Neoplasms; Lymphoma, Non-Hodgkin | Details |
IMPT-314 | IMPT-314 | Phase 2 Clinical | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details | |
CD20 monoclonal antibody(The First Affiliated Hospital of Soochow University) | Phase 2 Clinical | The First Affiliated Hospital Of Soochow University | Anemia, Aplastic | Details | |
CD19/CD20 bispecific CAR-T cells (Shanghai Cellular) | Phase 2 Clinical | Shanghai Cellular Biopharmaceutical Group Ltd | Lymphoma, B-Cell | Details | |
ALETA-001 | ALETA-001 | Phase 2 Clinical | Aleta BioTherapeutics Inc | Leukemia; Hematologic Neoplasms; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin | Details |
Rituximab Biosimilar (Istituto Giannina Gaslini) | Phase 2 Clinical | Istituto Giannina Gaslini | Nephrotic Syndrome | Details | |
1-A-46 | BR-110; 1A46; 1-A-46; CMG1A46; CMG1A-46; BR110 | Phase 2 Clinical | Chengdu Chimagen Biosciences Co Ltd, Hisun Biopharmaceutical Co Ltd, BioRay Pharmaceutical Co Ltd | Lymphoma, B-Cell; Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details |
ICP-B02 | CM-355; ICP-B02 | Phase 2 Clinical | Beijing Tiannuo Jiancheng Pharmaceutical Technology Co Ltd, Keymed Biosciences Co Ltd | Hematologic Neoplasms; Hematoma; Lymphoma; Lymphoma, Non-Hodgkin | Details |
TQB-2825 | TQB-2825 | Phase 2 Clinical | Wuxi Biologics Co Ltd | Lymphoma, B-Cell, Marginal Zone; Hematologic Neoplasms; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell | Details |
CD19/CD20 dual-target CAR-T cell therapy (Shenzhen University General Hospital) | Phase 2 Clinical | Shenzhen University General Hospital | Lymphoma, B-Cell | Details | |
JMT-601 | JMT-601 | Phase 2 Clinical | Shanghai Jmt-Bio Inc | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin | Details |
Prizloncabtagene autoleucel | JNJ-4496; EXP-039; C-CAR039; C-CAR-039; C CAR 039; EXP0-039; JNJ-90014496 | Phase 2 Clinical | Cellular Biomedicine Group Ltd | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin | Details |
EX-103 | EX-103; EX103 | Phase 2 Clinical | Guangzhou Excelmab Inc | Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Anti-CD19 and anti-CD20 CAR-T cell therapy (Medical College of Wisconsin) | Phase 2 Clinical | The Medical College Of Wisconsin Nonprofit | Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Burkitt Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Central Nervous System Lymphoma | Details | |
Anti-CD20 CAR T-cell therapy (Shanghai Longyao Biotechnology) | Phase 2 Clinical | Shanghai Longyao Biological Technology Co Ltd | Lymphoma, Large B-Cell, Diffuse | Details | |
MB-106 | MB-106 | Phase 2 Clinical | Fred Hutchinson Cancer Research Center | Lymphoma, B-Cell, Marginal Zone; Lymphoma, B-Cell; Leukemia, Lymphoid; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Waldenstrom Macroglobulinemia; Central Nervous System Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Imvotamab | IGM-2323 | Phase 1 Clinical | Igm Biosciences Inc | Lymphoma, B-Cell, Marginal Zone; Myositis; Autoimmune Diseases; Lupus Erythematosus, Cutaneous; Lymphoma, Large B-Cell, Diffuse; Arthritis, Rheumatoid; Lupus Erythematosus, Systemic; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Arthritis | Details |
Recombinant Fc-glycosylated anti-CD20 monoclonal antibody (Bio-Thera Solutions) | BAT-4306F | Phase 1 Clinical | Bio-Thera Solutions Ltd | Lymphoma, Non-Hodgkin | Details |
TRS-005 | TRS-005 | Phase 1 Clinical | Zhejiang Teruisi Pharmaceutical Inc | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin | Details |
Rituximab biosimilar (International Biotech Center Generium) | GNR-006 | Phase 1 Clinical | International Biotech Center Generium | Lymphoma, B-Cell | Details |
Recombinant anti-CD20 chimeric monoclonal antibody (Livzon Group) | LZM-002 | Phase 1 Clinical | Livzon Pharmaceutical Group Inc | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin | Details |
Humanized anti-CD19 and anti-CD20 dual specific CAR-T cell therapy (Fujian Medical University) | Phase 1 Clinical | Fujian Medical University | Lymphoma, Large B-Cell, Diffuse | Details | |
Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein (Fred Hutchinson Cancer Research Center) | Phase 1 Clinical | Fred Hutchinson Cancer Research Center, National Cancer Institute | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Burkitt Lymphoma; Lymphoma, Non-Hodgkin | Details | |
Rituximab biosimilar (Fred Hutchinson Cancer Research Center) | Phase 1 Clinical | Fred Hutchinson Cancer Research Center | Lymphoma, Large B-Cell, Diffuse; Multicentric Castleman's Disease (MCD); Burkitt Lymphoma; Sarcoma, Kaposi | Details | |
Anti-CD20 allogeneic CAR-T cell therapy (Nanjing Medical University) | LUCAR-20S | Phase 1 Clinical | Nanjing Legend Biotechnology Co Ltd | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Bendamustine Hydrochloride/Rituximab | Phase 1 Clinical | 1globe Biomedical Co Ltd | Lymphoma, B-Cell | Details | |
Rituximab biosimilar (Gedeon Richter) | RGB-03 | Phase 1 Clinical | Gedeon Richter | Arthritis, Rheumatoid | Details |
CD20-directed CAR-T cell therapy (Cellular Biomedicine) | C-CAR066 | Phase 1 Clinical | Cellular Biomedicine Group Inc | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin | Details |
YT-19/20 | Phase 1 Clinical | China Immunotech Co Ltd | Lymphoma, B-Cell; Leukemia; Lymphoma, Large B-Cell, Diffuse; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details | |
TriCAR T-cells | Phase 1 Clinical | Children'S Hospital Los Angeles | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
ICG-132 | ICG-132 | Phase 1 Clinical | iCell Gene Therapeutics LLC | Lymphoma, B-Cell | Details |
Dual Anti-CD19/Anti-CD20 CAR T-Cells (NCI) | Phase 1 Clinical | National Cancer Institute | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Hodgkin Disease; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Primary mediastinal B cell lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
CD19/CD20 CAR-T | Phase 1 Clinical | Persongen Biotherapeutics (Suzhou) Co Ltd | Hematologic Neoplasms; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
Anti-CD10 CAR T-cell therapy (Zhujiang Hospital/Nanfang Hospital) | Phase 1 Clinical | Southern Medical University Zhujing Hospital | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
JS-203 | JS-203 | Phase 1 Clinical | Shanghai Junshi Biological Engineering Co Ltd | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details |
P-CD19CD20-ALLO1 | P-CD19CD20-ALLO1 | Phase 1 Clinical | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular | Details | |
KITE-363 | KITE-363 | Phase 1 Clinical | Kite Pharma | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse | Details |
ACE-1831 | ACE-1831 | Phase 1 Clinical | Acepodia Biotech Inc | Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Primary mediastinal B cell lymphoma; Lymphoma, Non-Hodgkin | Details |
CD19/CD20 bispecific chimeric antigen receptor (CAR)-T cell therapy (Jonsson Comprehensive Cancer Center) | Phase 1 Clinical | Uclas Jonsson Comprehensive Cancer Center | Lymphoma, B-Cell; Leukemia, Lymphoid; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
AcNK-Sup003 | AcNK-Sup003 | Phase 1 Clinical | SupermAb (BeiJing) Biotech Co Ltd | Lymphoma, B-Cell | Details |
CD19/CD22-targeting CAR-T Cells therapy(Prekin Biopharmaceutical) | PRG2302; PRG-2302 | Phase 1 Clinical | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
P-CD19 x CD20 - ALLO1 | RG6540; RG-6540 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Lymphoma, B-Cell | Details |
MRG001 | MRG-001 | Phase 1 Clinical | Shanghai Miracogen Inc | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details |
JWCAR-201 | JWCAR-201; JWCAR201 | Phase 1 Clinical | Shanghai Ming Ju Biotechnology Co Ltd | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Autoimmune Diseases; Lupus Erythematosus, Systemic | Details |
Anti-CD20/CD30-CAR-T Cell therapy(Shanghai Tongji Hospital) | Phase 1 Clinical | Shanghai Tongji Hospital | Lymphoma, B-Cell; Leukemia, B-Cell; Lymphoma | Details | |
LUCAR-G39D | LUCAR-G39D | Phase 1 Clinical | Nanjing Legend Biotechnology Co Ltd | Lymphoma, B-Cell | Details |
LUCAR-G39P | LUCAR-G39P | Phase 1 Clinical | Nanjing Legend Biotechnology Co Ltd | Lymphoma, Non-Hodgkin | Details |
Allogenic Chimeric Antigen Receptor(CAR)-T Cell Therapy(Beijing Cancer Hospital) | LUCAR-20SP | Phase 1 Clinical | Beijing Cancer Hospital | Lymphoma, B-Cell | Details |
Rituximab biosimilar (Mabscale) | Phase 1 Clinical | Mabscale LLC | Arthritis, Rheumatoid | Details | |
JNJ-1493 | JNJ-1493 | Phase 1 Clinical | Xencor Inc | Hematologic Neoplasms; Lymphoma, B-Cell | Details |
C-CAR168 CAR T-cell therapy (AbelZeta) | C-CAR168 | Phase 1 Clinical | Cellular Biomedicine (Shanghai) Co Ltd | Myasthenia Gravis; Multiple Sclerosis, Relapsing-Remitting; Autoimmune Diseases; Lupus Erythematosus, Systemic; Neuromyelitis Optica; Muscular Diseases | Details |
GF-CART01 | GF-CART01 | Phase 1 Clinical | GenomeFrontier Therapeutics TW Co Ltd | Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Primary mediastinal B cell lymphoma; Lymphoma, Follicular; Waldenstrom Macroglobulinemia; Burkitt Lymphoma | Details |
SCTB-35 | SCTB35; SCTB-35 | Phase 1 Clinical | SinoCelltech Ltd | Lymphoma, B-Cell; Autoimmune Diseases; Lupus Erythematosus, Systemic | Details |
Recombinant human anti-CD20 momoclonal antibody(Shanghai Crosslink Pharma) | Phase 1 Clinical | Shanghai Crosslink Pharmaceutical R & D Co Ltd | Myasthenia Gravis; Pemphigus | Details | |
IMPT-514 | IMPT-514 | Phase 1 Clinical | ImmPACT Bio USA Inc | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Myositis; Multiple Sclerosis; Lupus Nephritis; Lupus Erythematosus, Systemic | Details |
INT-2104 | INT-2104 | Phase 1 Clinical | Interius BioTherapeutics Inc | Lymphoma, B-Cell; Hematologic Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells(NIH) | Phase 1 Clinical | National Cancer Institute | Lymphoma, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
RO-7121932 | RO7121932; RO-7121932; RO 7121932; RG-6035 | Phase 1 Clinical | Genentech Inc | Multiple Sclerosis | Details |
TanCART19/20 | Phase 1 Clinical | Pla General Hospital | Neuromyelitis Optica | Details | |
LCAR-AIO | LCAR-AIO; VHH CAR-T | Phase 1 Clinical | Nanjing Legend Biotechnology Co Ltd | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lupus Erythematosus, Systemic; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
Rituximab biosimilar (Zhejiang Teruisi Pharmaceutical) | TRS001 | Phase 1 Clinical | Zhejiang Teruisi Pharmaceutical Inc | Lymphoma | Details |
QLP-31907 | QLP-31907; QLP31907; PSB-202 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Waldenstrom Macroglobulinemia; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
ADI-001 | ADI-001 | Phase 1 Clinical | Regeneron Pharmaceuticals Inc, Adicet Bio Inc | Lymphoma, B-Cell, Marginal Zone; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Myositis; Lymphoma, Large B-Cell, Diffuse; Stiff-Person Syndrome; Autoimmune Diseases; Scleroderma, Systemic; Lupus Nephritis; Primary mediastinal B cell lymphoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lupus Erythematosus, Systemic; Lymphoma, Non-Hodgkin; Burkitt Lymphoma | Details |
CD19/CD20 CAR-T Cell Therapy (PersonGen) | Phase 1 Clinical | Persongen Biotherapeutics | Details | ||
LY007 | LY007 | Phase 1 Clinical | Shanghai Longyao Biological Technology Co Ltd | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin | Details |
Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T cell therapy (First Affiliated Hospital of Zhejiang University) | Phase 1 Clinical | First Affiliated Hospital Of Zhejiang University | Lymphoma, Large B-Cell, Diffuse | Details | |
Plamotamab | XmAb-13676 | Phase 1 Clinical | Xencor Inc | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
CD20/CD22 dual Targeted CAR T-cell therapy (Zhejiang University) | Phase 1 Clinical | Zhejiang University, Shanghai YaKe Biotechnology Co Ltd | Hematologic Neoplasms | Details | |
Rituximab/Paclitaxel | AR-160 | Phase 1 Clinical | Mayo Clinic | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Anti-CD20 CAR-T cell therapy (Wuhan Bio-Raid) | Clinical | Wuhan BioRaid Biotechnology Co Ltd | Neoplasms | Details | |
KJ-C2219 | KJ-C2219 | Clinical | CARsgen Therapeutics Holdings Ltd | Hematologic Neoplasms; Lymphoma, B-Cell | Details |
Anti-CD20 chimeric antigen receptor T cell therapy (Yake Biotechnology) | Clinical | Shanghai YaKe Biotechnology Co Ltd | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
Rituximab biosimilar (Bioxpress) | BXT-2336; BX 2336 | Clinical | Bioxpress Therapeutics Sa | Granulomatosis with Polyangiitis; Microscopic Polyangiitis; Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin; Pemphigus; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Rituximab/Bendamustine/Cytarabine | Fondazione Italiana Linfomi Onlus | Details |
This web search service is supported by Google Inc.